Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Geron Corporation    GERN

Delayed Quote. Delayed  - 07/28 08:05:13 pm
2.66 USD   -3.27%
07/27 Geron Announces Conference Call to Discuss Second Quarter 2016 Fi..
07/13 Geron Announces Issuance of U.S. Patents Related to Imetelstat
05/06 GERON : reports 1Q loss
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/22/2016 07/25/2016 07/26/2016 07/27/2016 07/28/2016 Date
2.66(c) 2.64(c) 2.64(c) 2.75(c) 2.66 Last
861 525 675 437 983 160 1 474 252 687 938 Volume
-1.48% -0.75% 0.00% +4.17% -3.27% Change
More quotes
Financials ($)
Sales 2016 1,65 M
EBIT 2016 -42,0 M
Net income 2016 -39,1 M
Debt 2016 -
Yield 2016 -
Sales 2017 48,1 M
EBIT 2017 2,51 M
Net income 2017 3,18 M
Debt 2017 -
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales2016 265x
Capi. / Sales2017 9,08x
Capitalization 437 M
More Financials
Company
Geron Corp. discovers and develops therapeutic products for cancer.It is a clinical stage biopharmaceutical company, which develops a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.Geron was founded by Michael D. West on November 28, 1990 and is headquartered in Menlo Park,... 
More about the company
Surperformance© ratings of Geron Corporation
Trading Rating : Investor Rating :
More Ratings
Latest news on GERON CORPORATION
07/27 Geron Announces Conference Call to Discuss Second Quarter 2016 Financial Resu..
07/13 Geron Announces Issuance of U.S. Patents Related to Imetelstat
05/06 GERON : reports 1Q loss
05/05 Geron Corporation Reports First Quarter 2016 Financial Results and Recent Eve..
04/27 Geron Announces Conference Call to Discuss First Quarter 2016 Financial Resul..
04/20 Geron Announces Two Imetelstat Poster Presentations at the American Associati..
04/06 GERON : to Present at the Needham Healthcare Conference
04/05 Geron to Present at the Needham Healthcare Conference
03/30 GERON CORPORATION : Why Investors Are So Bullish on This Small Biotech
03/17 Geron Announces Presentations at American Association of Cancer Research Annu..
More news
Sector news : Bio Therapeutic Drugs
03:28pDJU.S. HOT STOCKS : Hot Stocks to Watch
02:56pDJCELGENE : Lifts Guidance as Revlimid Sales Rise
07/27DJVERTEX PHARMACEUTICALS : Pharma Loss Narrows as Cystic Fibrosis Drug Sales Grow
07/27DJAMGEN : Profit Rises 13%, 2016 Outlook Raised
07/27DJAMGEN : Profit Rises 13%, 2016 Outlook Raised -- Update
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
07/01 GERON : Announcing Imetelstat Patent Protection Through 2032
06/28 MY POST-BREXIT SHOPPING SPREE : Day One
06/24 Is Jakafi A Breakthrough For Incyte In Blood Cancers?
06/03 Is It Time To Invest In Stem Cell Biotechs?
06/01 The Outlook For Geron Corporation's Oncology Program
Advertisement
Chart GERON CORPORATION
Duration : Period :
Geron Corporation Technical Analysis Chart | GERN | US3741631036 | 4-Traders
Full-screen chart
Technical analysis trends GERON CORPORATION
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 7,50 $
Spread / Average Target 173%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
John A. Scarlett President, Chief Executive Officer & Director
Hoyoung Huh Chairman
Olivia K. Bloom Chief Financial Officer, Treasurer & Executive VP
Karin Eastham Independent Director
Robert Jay Spiegel Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GERON CORPORATION-43.18%437
AMGEN, INC.5.14%128 218
GILEAD SCIENCES, INC.-19.17%108 930
CELGENE CORPORATION-9.73%83 742
REGENERON PHARMACEUTIC..-23.54%43 617
VERTEX PHARMACEUTICALS..-23.70%23 748
More Results